Evaluation of Immunogenicity and Safety of GSK Biologicals' Tdap Booster Vaccine (Boostrix) in Young Adults, Administered 10 Years After Previous Tdap Boosting
Phase of Trial: Phase III
Latest Information Update: 02 Jan 2018
At a glance
- Drugs DTaP vaccine (Primary)
- Indications Diphtheria; Pertussis; Tetanus
- Focus Pharmacodynamics; Registrational
- Sponsors GlaxoSmithKline
- 25 Apr 2014 According to ClinicalTrials.gov record, status changed from active, no longer recruiting to completed.
- 18 Apr 2014 According to ClinicalTrials.gov record, status changed from recruiting to active, no longer recruiting.
- 24 Jan 2014 Planned End Date changed from 1 Jan 2014 to 1 May 2014 according to ClinicalTrials.gov record.